ReNeuron, the stem cell company, continued its meteoric rise after yesterday’s announcement that it had applied to US regulators to start clinical trials of its treatment for stroke patients. It shares doubled to 38.75p after five directors bought an average of 44,000 shares each at 19.5p.
One trader said the company had the potential to become the market leader in its field, while house broker Collins Stewart said the company is likely to “generate substantial newsflow in the next few weeks. We have a price target of 106p for the stroke programme alone”.
Primedia stock quotes
Primedia stock charts
Follow this thread
